Tevogen Inc. Common Stock (TVGN)
Stock · NASDAQ · Health Care
$7.07as of 10/16/2026
Price chart
Active signals
TVGN Signal Track Record
How signals performed across all stocks →What TVGN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 21 | +0.5% | 67% | September 1, 2026 |
| Volume Spike | 20 | -8.9% | 35% | June 26, 2026 |
| Bollinger Band Breakdown | 17 | -6.8% | 41% | September 28, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +1.3% | 67% | July 10, 2025 |
| Any 20-session window (baseline) | -2.7% | 42% |
Computed by MarketWall from daily closing prices since October 20, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TVGN
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune s…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 18
- Website
- tevogen.com/
Fundamentals
- 1-day range
- $6.75$6.9
- Market cap
- $41.58M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-6.80
- Dividend yield
- —
- Beta
- 0.27
- Avg. volume
- 8.8K
Tevogen Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TVGNTevogen Inc. Common Stock$7.07▼ 0.14%Market cap $41.58MP/E —$3.64$39
- ELUTElutia Inc. Class A Common Stock$0.794▲ 0.63%Market cap $38.95MP/E 0.67$0.5$1.39
- DYAIDyadic International Inc. Common Stock$0.41▼ 2.38%Market cap $37.17MP/E —$0.3401$1.6
- MGXMetagenomi Therapeutics Inc. Common Stock$0.784▼ 7.22%Market cap $46.68MP/E —$0.86$3.95
- EXOZeXoZymes Inc. Common Stock$4.09▲ 2.25%Market cap $47.57MP/E —$4.35$18.4
- ALGSAligos Therapeutics Inc. Common Stock$4.86▼ 9.83%Market cap $34.10MP/E —$3.98$13.69
- ATYRaTyr Pharma Inc. Common Stock$0.174▼ 5.43%Market cap $49.22MP/E —$0.2$1.11
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TVGN Tevogen Inc. Common Stock | $41.58M | — | $7.07 | ▼ 0.14% | $3.64$39 |
| ELUT Elutia Inc. Class A Common Stock | $38.95M | 0.67 | $0.794 | ▲ 0.63% | $0.5$1.39 |
| DYAI Dyadic International Inc. Common Stock | $37.17M | — | $0.41 | ▼ 2.38% | $0.3401$1.6 |
| MGX Metagenomi Therapeutics Inc. Common Stock | $46.68M | — | $0.784 | ▼ 7.22% | $0.86$3.95 |
| EXOZ eXoZymes Inc. Common Stock | $47.57M | — | $4.09 | ▲ 2.25% | $4.35$18.4 |
| ALGS Aligos Therapeutics Inc. Common Stock | $34.10M | — | $4.86 | ▼ 9.83% | $3.98$13.69 |
| ATYR aTyr Pharma Inc. Common Stock | $49.22M | — | $0.174 | ▼ 5.43% | $0.2$1.11 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Saadi Ryan H. · September 14, 2026 · Grant8.00M
- Desai Kirti · September 14, 2026 · Grant750.0K
- Goh Keow Lin · September 11, 2026 · Grant75.0K
- Sordillo Victor J. · September 11, 2026 · Grant75.0K
- Feike Jeffrey L. · September 11, 2026 · Grant75.0K
- Patton Curtis L. · September 11, 2026 · Grant75.0K
- PODLOGAR SUSAN M · September 11, 2026 · Grant75.0K
- Sordillo Victor J. · July 10, 2026 · Grant40.0K
- Saadi Ryan H. · July 10, 2026 · Grant1.22M
- Patton Curtis L. · July 10, 2026 · Grant40.0K
- Goh Keow Lin · July 10, 2026 · Grant40.0K
- Feike Jeffrey L. · July 10, 2026 · Grant40.0K
- Desai Kirti · July 10, 2026 · Grant40.0K
- PODLOGAR SUSAN M · July 10, 2026 · Grant40.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 129.5K
- Total value held
- $585.4K
- Institutional holders
- 27
- Unknown33.2K
- Unknown24.4K
- Unknown17.3K
- Unknown15.7K
- Unknown15.3K
- Unknown10.2K
- Unknown5.8K
- Unknown3.6K
- Unknown1.0K
- Unknown941
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Tevogen Regains Nasdaq Listing Compliance
Tevogen Inc. has regained compliance with Nasdaq Global Market continued listing requirements. This development addresses potential delisting risks associated with the company's stock status. The news provides regulatory clarity for the ticker, which has seen significant price volatility over the past year.
Tevogen Regains Nasdaq Listing Compliance. Tevogen Inc. has regained compliance with Nasdaq Global Market continued listing requirements. This development addresses potential delisting risks associated with the company's stock status. The news provides regulatory clarity for the ticker, which has seen significant price volatility over the past year.